{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:13:16Z","timestamp":1789809196738,"version":"4.0.1"},"reference-count":34,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Endometrial carcinoma (EC) is a common gynecologic malignancy with rising incidence globally, including in low- and middle-income countries. Local data on clinicopathological characteristics, treatment patterns, and survival outcomes remain limited in Pakistan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 622 women aged \u226518 years with histologically confirmed EC treated at Shaukat Khanum Memorial Cancer Hospital and Research Centre between 2010 and 2020. Clinical, pathological, treatment, and outcome data were extracted from the institutional electronic medical records. Survival outcomes were estimated using Kaplan\u2013Meier analysis, and prognostic factors were evaluated using Cox proportional hazards regression. Statistical analyses were conducted using IBM SPSS Statistics 27.0. The study was approved by the Institutional Review Board of Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan (IRB exemption number EX-17-12-25-01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median age was 56 years (range 24\u201387), and 36.3% were aged \u226560 years. Mean BMI was 32.8 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , reflecting a high prevalence of obesity. Most patients presented with FIGO stage I disease (71.4%), and deep myometrial invasion (\u226550%) was present in 47.7%. Nodal metastasis was identified in 5.8%. Primary surgical treatment was performed in 94.4% of patients, with frequent use of adjuvant radiotherapy (57.2%), brachytherapy (60.6%), and chemotherapy (83.6%). The 5-year overall survival (OS) was 88.6% (95% CI: 85.6\u201391.7). On multivariate analysis, FIGO stage, nodal status, age and BMI were independent predictors of Overall Survival (OS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Key prognostic factors in EC, including age, stage, nodal involvement, histology, and performance status, are consistent with international and Asian data. Regional differences in age at diagnosis, obesity prevalence, and histologic distribution highlight the need for context-specific management strategies in LMICs. Prospective studies incorporating molecular profiling may further refine risk stratification and improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/jcas-2026-0015","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:31:36Z","timestamp":1789806696000},"page":"97-104","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Outcomes and Prognostic Analysis of Endometrial Cancer: A 10-Year Tertiary Care Experience"],"prefix":"10.2478","volume":"12","author":[{"given":"Sadia","family":"Anjum","sequence":"first","affiliation":[{"name":"Resident, Department of Clinical and Radiation Oncology , Shaukat Khanum Memorial Cancer Hospital & Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Tahseen","sequence":"additional","affiliation":[{"name":"Resident, Department of Clinical and Radiation Oncology , Shaukat Khanum Memorial Cancer Hospital & Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqueel","family":"Shahid","sequence":"additional","affiliation":[{"name":"Fellow Neuro-Oncology , McGill University Health Centre , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabinda","family":"Sadaf","sequence":"additional","affiliation":[{"name":"Consultant, Department of Clinical and Radiation Oncology , Shaukat Khanum Memorial Cancer Hospital & Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Haider","sequence":"additional","affiliation":[{"name":"Resident, Department of Clinical and Radiation Oncology , Shaukat Khanum Memorial Cancer Hospital & Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Subhan","sequence":"additional","affiliation":[{"name":"Resident, Department of Clinical and Radiation Oncology , Shaukat Khanum Memorial Cancer Hospital & Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rameesha","family":"Jahangir","sequence":"additional","affiliation":[{"name":"Resident, Department of Clinical and Radiation Oncology , Shaukat Khanum Memorial Cancer Hospital & Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fajar Rafi","family":"Ranjha","sequence":"additional","affiliation":[{"name":"Fellow, Department of Clinical and Radiation Oncology , Shaukat Khanum Memorial Cancer Hospital & Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2026091908312594222_j_jcas-2026-0015_ref_001","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2022. CA Cancer J Clin. 2023;73:17\u201348.","DOI":"10.3322\/caac.21763"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_002","unstructured":"International Agency for Research on Cancer. GLOBOCAN 2022: Pakistan Fact Sheet. Lyon: IARC; 2024."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_003","doi-asserted-by":"crossref","unstructured":"Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120:383\u201397.","DOI":"10.1097\/AOG.0b013e3182605bf1"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_004","doi-asserted-by":"crossref","unstructured":"Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet. 2016;387:1094\u20131108.","DOI":"10.1016\/S0140-6736(15)00130-0"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_005","doi-asserted-by":"crossref","unstructured":"Colombo N, Creutzberg C, Amant F, et al. ESMO\u2013ESGO\u2013ESTRO consensus conference on endometrial cancer. Int J Gynecol Cancer. 2016;26:2\u201330.","DOI":"10.1097\/IGC.0000000000000609"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_006","unstructured":"Maheshwari A, Kumar N, et al. Endometrial cancer in Asia. Int J Gynecol Cancer. 2016;26:1303\u20139."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_007","doi-asserted-by":"crossref","unstructured":"Goel P, Singh V, Sharma R, et al. Early endometrial carcinoma outcomes. J Cancer Res Ther. 2023;19(Suppl 1):S318\u201322.","DOI":"10.4103\/jcrt.jcrt_920_21"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_008","doi-asserted-by":"crossref","unstructured":"Setakornnukul J, Petsuksiri J, et al. Long-term outcomes of patients with endometrial carcinoma treated with radiation. Asian Pac J Cancer Prev. 2014;15:2279\u201385.","DOI":"10.7314\/APJCP.2014.15.5.2279"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_009","doi-asserted-by":"crossref","unstructured":"Yamaguchi M, Kushiya N, Tamura R, et al. Trends in endometrial carcinoma: Experience of a single institute for four decades. Jpn J Clin Oncol. 2024;54:599\u2013605.","DOI":"10.1093\/jjco\/hyae012"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_010","unstructured":"Jamal S, Mamun AA, Khan S. Endometrial carcinoma: Five-year experience at a tertiary care hospital in Pakistan. J Ayub Med Coll Abbottabad. 2010;22:97\u2013100."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_011","unstructured":"Sultana N, Akram M, Wani A, et al. Clinicopathological profile of endometrial carcinoma at a tertiary care center in Pakistan. Pak J Med Sci. 2016;32:206\u201310."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_012","unstructured":"Yusuf AW, Wazir F, Mushtaq S. Endometrial adenocarcinoma: A clinicopathological study of 80 cases. J Pak Med Assoc. 2013;63:1092\u20135."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_013","unstructured":"Mahmood H, Rehman S, Qureshi S, et al. Presentation and treatment patterns in endometrial carcinoma at a tertiary care oncology center. J Coll Physicians Surg Pak. 2019;29:314\u20138."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_014","doi-asserted-by":"crossref","unstructured":"FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the corpus uteri. Int J Gynecol Obstet. 2009;105:109.","DOI":"10.1016\/j.ijgo.2009.02.010"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_015","doi-asserted-by":"crossref","unstructured":"Keys HM, Roberts JA, Brunetto VL, et al. GOG-99: A phase III trial of surgery \u00b1 pelvic radiation therapy in intermediate-risk endometrial carcinoma. Gynecol Oncol. 2004;92:744\u201351.","DOI":"10.1016\/j.ygyno.2003.11.048"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_016","doi-asserted-by":"crossref","unstructured":"Creutzberg CL, van Putten WLJ, Koper PC, et al. PORTEC-1: Postoperative radiotherapy in endometrial carcinoma. Lancet. 2000;355:1404\u201311.","DOI":"10.1016\/S0140-6736(00)02139-5"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_017","doi-asserted-by":"crossref","unstructured":"Nout RA, Smit VT, Putter H, et al. PORTEC-2: Vaginal brachytherapy versus pelvic radiotherapy in high-intermediate-risk endometrial carcinoma. Lancet. 2010;375:816\u201323.","DOI":"10.1016\/S0140-6736(09)62163-2"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_018","doi-asserted-by":"crossref","unstructured":"de Boer SM, Powell ME, Mileshkin LR, et al. PORTEC-3: Chemoradiotherapy versus radiotherapy for high-risk endometrial cancer. Lancet Oncol. 2018;19:295\u2013309.","DOI":"10.1016\/S1470-2045(18)30079-2"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_019","unstructured":"Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. Global patterns and trends in endometrial cancer incidence and survival. Int J Cancer. 2018;143:2237\u201348."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_020","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms. Version 2024."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_021","doi-asserted-by":"crossref","unstructured":"Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynecol Obstet. 2009;105:109.","DOI":"10.1016\/j.ijgo.2009.02.010"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_022","unstructured":"Wright JD, Barrena Medel NI, Sehouli J, et al. Contemporary management of endometrial cancer. Lancet. 2009;374:833\u201346."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_023","unstructured":"Fader AN, et al. Clear cell carcinoma of the uterus. Gynecol Oncol. 2010;116:10\u20136."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_024","unstructured":"Reed NS, Mangioni C, Malmstr\u00f6m H, et al. Uterine sarcomas: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29:iv51\u2013iv60."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_025","doi-asserted-by":"crossref","unstructured":"Renehan AG, Tyson M, Egger M, et al. Body-mass index and cancer incidence: A systematic review and meta-analysis. Lancet. 2008;371:569\u201378.","DOI":"10.1016\/S0140-6736(08)60269-X"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_026","unstructured":"Crosbie EJ, Zwahlen M, et al. Body mass index and endometrial cancer risk. Lancet Oncol. 2010;11:673\u201384."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_027","doi-asserted-by":"crossref","unstructured":"Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10\u20137.","DOI":"10.1016\/0090-8258(83)90111-7"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_028","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo E, Prat J. Uterine sarcomas: Diagnosis and management. Gynecol Oncol. 2010;116:131\u20139.","DOI":"10.1016\/j.ygyno.2009.09.023"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_029","doi-asserted-by":"crossref","unstructured":"Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366:491\u2013505.","DOI":"10.1016\/S0140-6736(05)67063-8"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_030","unstructured":"Lewin SN, et al. Survival by stage in endometrial cancer. Gynecol Oncol. 2010;119:15\u201320."},{"key":"2026091908312594222_j_jcas-2026-0015_ref_031","doi-asserted-by":"crossref","unstructured":"Guntupalli SR, Zighelboim I, et al. Lymphovascular space invasion and survival outcomes. Gynecol Oncol. 2012;124:31\u20135.","DOI":"10.1016\/j.ygyno.2011.09.017"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_032","doi-asserted-by":"crossref","unstructured":"Dos Reis R, et al. LVSI in low-risk endometrial carcinoma. Int J Gynecol Cancer. 2015;25:1292\u20139.","DOI":"10.1097\/IGC.0000000000000490"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_033","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","DOI":"10.3322\/caac.21590"},{"key":"2026091908312594222_j_jcas-2026-0015_ref_034","doi-asserted-by":"crossref","unstructured":"Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. N Engl J Med. 2022;386(5):437\u2013448.","DOI":"10.1056\/NEJMoa2108330"}],"container-title":["Journal of Cancer and Allied Specialties"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/jcas-2026-0015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:31:44Z","timestamp":1789806704000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/jcas-2026-0015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.2478\/jcas-2026-0015"],"URL":"https:\/\/doi.org\/10.2478\/jcas-2026-0015","relation":{},"ISSN":["2411-989X"],"issn-type":[{"value":"2411-989X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}